Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery

Colloids and Surfaces B: Biointerfaces

Volumn 147, Issue , 2016, Pages 376-386

  Hao, Jifu ^a   Zhao, Jing ^a   Zhang, Shupeng ^a   Tong, Tiantian ^a   Zhuang, Qiannan ^a   Jin, Kai ^a   Chen, Wei ^a   Tang, Hua ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Gellan gum; In situ gel; Intranasal drug delivery; Resveratrol

Indexed keywords

BIOCHEMISTRY; EFFICIENCY; FLUORESCENCE MICROSCOPY; GELATION; PARTICLE SIZE; PHARMACOKINETICS; RESIDENCE TIME DISTRIBUTION; SHEAR THINNING; VISCOSITY; YIELD STRESS;

EFFICIENCY STUDIES; GELLAN GUM; INTRANASAL; INTRAVENOUS ADMINISTRATION; MATHEMATIC MODEL; MUCOSAL PERMEABILITY; RHEOLOGICAL PROPERTY; SITU GELS;

RESVERATROL;

GELLAN; NANOCOMPOSITE; NANOPARTICLE; RESVERATROL; ANTIOXIDANT; DRUG CARRIER; GEL; STILBENE DERIVATIVE; SUSPENSION;

ADHESION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL PARAMETERS; CHEMICAL STRESS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; FLOW KINETICS; FLUORESCENCE MICROSCOPY; GEL; GELATION; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MEMBRANE PERMEABILITY; MOUSE; NANOTECHNOLOGY; NONHUMAN; NOSE CAVITY; NOSE MUCOSA; PARTICLE SIZE; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SUSPENSION; SYNTHESIS; THIXOTROPY; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY; ADMINISTRATION AND DOSAGE; ANIMAL; BIOAVAILABILITY; BRAIN; CHEMISTRY; METABOLISM; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BRAIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GELS; MICE; NANOPARTICLES; NASAL MUCOSA; STILBENES; SUSPENSIONS; TISSUE DISTRIBUTION; VISCOSITY;

EID: 84989903793     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.08.011     Document Type: Article

References (33)

1. [1] Gaia, C., Luca, L., Elisa, Z., Viola, G., Fabio, S., Anna Giulia, B., Giampiero, P., Alessandro, G., Laura, C., Alessandra, S., Brain distribution of ribavirin after intranasal administration. Antiviral Res. 92 (2011), 408–414.
2. [2] Alpesh, M., Snjezana, S., Lisbeth, I., Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 379 (2009), 146–157.
3. [3] Lusine, D., Richard, S.F., Andreas, A.M., Felix, B., Stephan, V., Marine, B., Ali, L., Tim, K., Felix, S., Barbara, S., Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 14 (2011), 3–16.
4. [4] Zheng, C., Song, X., Feng, S., Yang, Z., Hou, S., Liu, Z., Formulation and evaluation of In situ gelling systems for intranasal administration of gastrodin. AAPS Pharmscitech. 12 (2011), 1102–1109.
5. [5] Galgatte, U.C., Kumbhar, A.B., Chaudhari, P.D., Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv. 21 (2013), 62–73.
6. [6] Izumi, Y., Kikuta, N., Sakai, K., Takezawa, H., Phase diagrams and molecular structures of sodium-salt-type gellan gum. Carbohydr. Polym. 30 (1996), 121–127.
7. [7] Cao, S., Ren, X., Zhang, Q., Xu, E.F., Chen, J., Liu, L., Jiang, X., In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int. J. Pharm. 365 (2009), 109–115.
8. [8] Patil, S.B., Sawant, K.K., Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery. J. Microencapsulation 26 (2009), 432–443.
9. [9] Richard, T., Pawlus, A.D., Iglésias, M.L., Pedrot, E., Waffo-Teguo, P., Mérillon, J.M., Monti, J.P., Neuroprotective properties of resveratrol and derivatives. Ann. N. Y. Acad. Sci. 1215 (2011), 103–108.
10. [10] Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., Parekh, H.S., Popat, A., Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach. J. Colloid Interface Sci. 462 (2015), 368–374.
11. [11] Carletto, B., Berton, J., Ferreira, T.N., Dalmolin, L.F., Paludo, K.S., Mainardes, R.M., Farago, P.V., Favero, G.M., Resveratrol-loaded nanocapsules inhibit murine melanoma tumor growth. Colloids Surf. B Biointerfaces 144 (2016), 65–72.
12. [12] Zhou, Z., Li, W., Sun, W.J., Lu, T., Tong, H.H.Y., Sun, C.C., Zheng, Y., Resveratrol cocrystals with enhanced solubility and tabletability. Int. J. Pharm. 509 (2016), 391–399.
13. [13] Summerlin, N., Qu, Z., Pujara, N., Sheng, Y., Jambhrunkar, S., Mcguckin, M., Popat, A., Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol. Colloids Surf. B Biointerfaces 144 (2016), 1–7.
14. [14] Hao, J., Yun, G., Jing, Z., Zhang, J., Li, Q., Zhao, Z., Liu, J., Preparation and optimization of resveratrol nanosuspensions by antisolvent precipitation using box-Behnken design. AAPS Pharmscitech. 16 (2014), 118–128.
15. [15] Summerlin, N., Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., Popat, A., Resveratrol nanoformulations: challenges and opportunities. Int. J. Pharm. 479 (2015), 282–290.
16. [16] Lorin, M.I., Gaerlan, P.F., Mandel, I.D., Quantitative composition of nasal secretions in normal subjects. J. Lab. Clin. Med. 80 (1972), 275–281.
17. [17] Chingunpituk, J., Nanosuspension technology for drug delivery. Walailak J. Sci. Technol., 4, 2007.
18. [18] Mao, R., Tang, J., Swanson, B.G., Water holding capacity and microstructure of gellan gels. Carbohydr. Polym. 46 (2001), 365–371.
19. [19] Baloglu, E., Karavana, S.Y., Senyigit, Z.A., Guneri, T., Rheological and mechanical properties of poloxamer mixtures as a mucoadhesive gel base. Pharm. Dev. Technol. 16 (2011), 627–636 (610).
20. [20] Mahdi, M.H., Conway, B.R., Smith, A.M., Development of mucoadhesive sprayable gellan gum fluid gels. Int. J. Pharm. 488 (2015), 12–19.
21. [21] Chow, H.H.S., Zhi, C., Matsuura, G.T., Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 88 (1999), 754–758.
22. [22] Abdelbary, G.A., Tadros, M.I., Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies. Int. J. Pharm. 452 (2013), 300–310.
23. [23] Fazil, M., Md, S., Haque, S., Kumar, M., Baboota, S., Sahni, J.K., Ali, J., Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 47 (2012), 6–15.
24. [24] Saindane, N.S., Pagar, K.P., Vavia, P.R., Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and In vivo characterization. AAPS Pharmscitech. 14 (2013), 189–199.
25. [25] Belgamwar, V.S., Chauk, D.S., Mahajan, H.S., Jain, S.A., Gattani, S.G., Surana, S.J., Formulation and evaluation of in situ gelling system of dimenhydrinate for nasal administration. Pharm. Dev. Technol. 14 (2009), 240–248.
26. [26] Takahiro, F., Sakie, N., Makoto, N., Sayaka, I., Rheo, T., Saphwan, A.A., Shinya, I., Katsuyoshi, N., Phillips, G.O., Molecular structures of gellan gum imaged with atomic force microscopy in relation to the rheological behavior in aqueous systems in the presence or absence of various cations. J. Agric. Food Chem. 56 (2008), 8609–8618.
27. [27] Andrews, G.P., Jones, D.S., Rheological characterization of bioadhesive binary polymeric systems designed as platforms for drug delivery implants. Biomacromolecules 7 (2006), 899–906.
28. [28] Jones, D.S., Woolfson, A.D., Brown, A.F., Textural, viscoelastic and mucoadhesive properties of pharmaceutical gels composed of cellulose polymers. Int. J. Pharm. 151 (1997), 223–233.
29. [29] Amri, A., Chaumeil, J.C., Sfar, S., Charrueau, C., Administration of resveratrol: what formulation solutions to bioavailability limitations?. J. Controlled Release 158 (2012), 182–193.
30. [30] Dhuria, S.V., Hanson, L.R., Frey, W.H., Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99 (2010), 1654–1673.
31. [31] Shadab, M., Khan, R.A., Gulam, M., Krishna, C., Sanjula, B., Sahni, J.K., Javed, A., Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model. Eur. J. Pharm. Sci. 48 (2012), 393–405.
32. [32] Wang, F., Jiang, X.W., Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int. J. Pharm. 263 (2003), 1–7.
33. [33] Al Ghananeem, A.M., Saeed, H.R., Yokel, R.A., Malkawi, A.H., Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J. Drug Target 18 (2010), 381–388.